Abstract
Material: A prospective, observational study was performed recruiting all patients who started risankizumab treatment for moderate-to-severe psoriasis. We carried out a 4-week length follow up in order to evaluate the effectiveness in real world practice. Our cohort was made of 15 patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
